Here, we describe a protocol to analyze the phenotype of regulatory T (Treg) cells isolated from naïve and chronic lymphocytic choriomeningitis virus-infected mice. In addition, we provide a process to evaluate the suppressive activity of the Treg cells.
Regulatory T (Treg) cells, which express Foxp3 as a transcription factor, are subsets of CD4+ T cells. Treg cells play crucial roles in immune tolerance and homeostasis maintenance by regulating the immune response. The primary role of Treg cells is to suppress the proliferation of effector T (Teff) cells and the production of cytokines such as IFN-γ, TNF-α, and IL-2. It has been demonstrated that Treg cells' ability to inhibit the function of Teff cells is enhanced during persistent pathogen infection and cancer development. To clarify the function of Treg cells under resting or inflamed conditions, a variety of in vitro suppression assays using mouse or human Treg cells have been devised. The main aim of this study is to develop a method to compare the differences in phenotype and suppressive function between resting and activated Treg cells. To isolate activated Treg cells, mice were infected with lymphocytic choriomeningitis virus (LCMV) clone 13 (CL13), a chronic strain of LCMV. Treg cells isolated from the spleen of LCMV CL13-infected mice exhibited both the activated phenotype and enhanced suppressive activity compared with resting Treg cells isolated from naïve mice. Here, we describe the basic protocol for ex vivo phenotype analysis to distinguish activated Treg cells from resting Treg cells. Furthermore, we describe a protocol for the measurement of the suppressive activity of fully activated Treg cells.
Regulatory T (Treg) cells express forkhead box P3 (Foxp3) as a transcription factor for their development and function1. Additionally, Treg cells express various other molecules such as CD252, lymphocyte-activation gene 3 (LAG-3)3, glucocorticoid-induced tumor necrosis factor receptor4, and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)5 on their surface or intracellular region. During chronic infection with various kinds of pathogens such as viruses6,7, bacteria8,9, and parasites10-12, or in the course of cancer development13,14, Treg cells become differentiated into activated cells, displaying enhanced suppressive function targeting effector CD4+ and CD8+ T cells. A number of papers have suggested that expanded and activated Treg cells contribute to the impaired CD8+ T cell response during friend retrovirus (FV) infection15-17. FV-induced Treg cells inhibit IFN-γ or granzyme B expression and cytotoxic reactivity of CD8+ T cells15-17. Moreover, in a herpes simplex virus infection model, it was reported that depletion of CD4+CD25+ Treg cells resulted in expansion of virus-specific CD8+ T cells and severe tissue damage by infiltration of immunopathogenic CD4+ T cells18-20.
Mice infected chronically with the clone 13 strain of lymphocytic choriomeningitis virus (LCMV CL13)21-24 have been widely used to characterize the phenotype and function of effector T cells (Teff) and Treg cells during chronic virus infection. During persistent LCMV infection, virus-specific Teff cells progressively lose their effector function and become exhausted T (Texh) cells. On the other hand, Treg cells reinforce their ability to suppress virus-specific T cell response25. The decrease in the functioning capacity of the Teff cells can be explained by several factors such as upregulation of inhibitory receptors on Teff cells, altered function of antigen-presenting cells, production of immunoregulatory cytokines, and increased frequency or enhanced function of Treg cells26. Among the factors involved in T cell suppression, programmed cell death protein-1 (PD-1)-expressing Texh cells and Treg cells have been widely considered as the hallmarks of antigen persistence and suppressive environment. Recently, it was reported that blockade of the PD-1 pathway and ablation of Treg cells lead to enhanced T cell function and decreased viral load during LCMV chronic infection27. Furthermore, Treg cells are activated during chronic infection of mice with LCMV23,25 and their suppressive function is strengthened25. PD-1 is highly expressed on Treg cells as well as Texh cells, and the level of PD-1 expressed by Treg cells correlates with the strength of their suppressive function to inhibit T cell proliferation25.
Here, we describe a method to compare the characteristics of activated Treg cells isolated from mice infected with LCMV CL13 and resting Treg cells isolated from naïve mice. Furthermore, we explain a series of processes to separate activated Treg cells and examine their ex vivo phenotype, as well as measure their suppressive activity in vitro.
In this study, mice were maintained in a specific pathogen-free facility of the Yonsei Laboratory Animal Research Center of Yonsei University. All animal experiments were conducted in accordance with the Korean Food and Drug Administration guidelines using protocols approved by the International Animal Care and Use Committee of the Yonsei Laboratory Animal Research Center at Yonsei University.
1. Preparation of Solutions
2. Isolation of Splenic Lymphocytes
3. Phenotyping of Splenic Conventional T (Tconv) Cells and Treg Cells
NOTE: Before Treg cell isolation, examine the phenotype of splenic lymphocytes isolated from naïve or infected mice by staining the cells with various antibodies and analyzing them by flow cytometry.
4. Isolation of CD4+CD25+ Treg Cells
NOTE: The volumes of all reagents indicated below are for a starting cell number of 1 x 107 total splenocytes.
5. Isolation of CD8+ T Cells and Labeling of CD8+ T Cells
NOTE: The volumes of all reagents indicated below are for a starting cell number of 1 x 107 total splenocytes.
6. Setting Up the In Vitro Suppression Assay Using CD4+CD25+ Treg and CD8+ T Cells
7. Analysis of CD8+ T Cell Proliferation & Cytokine Production from CD8+ T Cells
We generated mice with persistent virus infection by injecting them with 2 x 106 p.f.u. of LCMV CL13 intravenously. To investigate the phenotypic changes in Treg cells and Tconv cells during chronic virus infection, splenic lymphocytes obtained from naïve and infected mice were stained with various antibodies and analyzed by flow cytometry. At 16 d p.i., PD-1 was upregulated in both Foxp3–CD4+ Tconv (Figure 1A, upper panel) and Foxp3–CD8+ Tconv (Figure 1B, upper panel) cells. The frequency of Foxp3+CD4+ Treg cells was two times higher in the LCMV CL13-infected mice than in the naïve mice (Figure 1A). In particular, most of the Foxp3+CD4+ Treg cells displayed the activated phenotype, expressing high levels of PD-1 at this time point (Figure 1A).
For the in vitro suppression assay, a considerable number of CD8+ Tconv cells and CD4+CD25+ Treg cells were required. To obtain 1 x 107 cell proliferation tracking violet dye-labeled CD8+ T cells, splenocytes from two spleens of naïve mice were pooled. To obtain 2 x 106 or 3 x 106 of CD4+CD25+ Treg cells, at least three spleens from naive and LCMV CL13-infected mice, respectively, were pooled. CD8+ T cells as Tresp cells were separated successfully without significant contamination with other immune cells (Figure 2A). Treg cells could also be isolated, with a dominant population of CD25+CD4+ T cells with more than 80% purity (Figure 2B).
To compare the suppressive function of naïve and chronic Treg cells, the isolated Treg and Tresp cells were incubated together under stimulation with anti-CD3/CD28-coated beads at 37 °C for 3 days. % inhibition of CD8+ Tresp cell proliferation was increased in a Treg cell dese-dependent manner (Figure 3A). When CD8+ Tresp cells were co-cultured with chronic Treg cells in a ratio of 1:1, proliferation of CD8+ Tresp cells were significantly inhibited (Figure 3B). IFN-γ production by CD8+ Tresp cells were also significantly inhibited when CD8+ Tresp cells were co-cultured with activated Treg cells from chronically infected mice rather than with resting Treg cells from naïve mice in a Treg cell dose-dependent manner (Figure 3C).
Figure 1: Phenotypes of CD4+ and CD8+ T cells in the spleen of naïve mice or LCMV CL13-infected mice at 16 d p.i. (A) Expression of PD-1 or CD25 on Foxp3–CD4+ Tconv and Foxp3+CD4+ Treg cells. (B) Expression of PD-1 or CD25 on Foxp3–CD8+ Tconv cells. Splenic lymphocytes were stained with antibodies against CD4, CD8, CD25, PD-1, and Foxp3. Data are representative of three independent experiments. Panel A has been modified from25 as a reference. Please click here to view a larger version of this figure.
Figure 2: Purities of Tresp cells isolated from naïve mice and Treg cells isolated from naïve or LCMV CL13-infected mice. (A) Percentage of CD8+ T cells after isolation. (B) Percentage of CD25-expressing CD4+ Treg cells after isolation. Each quadrant in (B) was determined by the expression levels of CD4 and CD25. Data are representative of three independent experiments. Please click here to view a larger version of this figure.
Figure 3: Effect of activated Treg cells on CD8+ T cell response. (A) % inhibition of CD8+ T cells co-cultured with Treg cells in a Treg cell dose-dependent manner. (B) Proliferation of CD8+ T cells co-cultured with Treg cells in 1:1 ratio. (C) IFN-γ production of CD8+ T cells co-cultured with Treg cells in a Treg cell dose-dependent manner. Proliferation of CD8+ T cells was measured by dilution of cell proliferation tracking violet dye in proliferated CD8+ T cells and IFN-γ secretion was evaluated by ELISA. Cell proliferation tracking violet dye-labeled CD8+ T cells were stimulated with anti-CD3/CD28-coated beads for 3 days in the absence or presence of Treg cells isolated from either naïve or chronically infected mice. In the histogram, the numbers without and with parenthesis indicate the proliferation percentage of CD8+ T cells co-cultured with and without Treg cells, respectively. Filled gray peaks in the histogram indicate proliferation of CD8+ T cells co-cultured without Treg cells. Each group was designed in triplicates. The bars represent mean + SEM. This figure has been modified from25 as a reference. Please click here to view a larger version of this figure.
Although only a small number of Treg cells exist in mice and humans, it is important to understand their function as they play a crucial role in regulating the immune response and maintaining immune tolerance. The number and suppressive functions of Treg cells increases during a chronic virus infection15-20 as well as cancer progression13,14. This is probably due to continued antigen stimulation. To evaluate the Treg cells function under antigen persistence and disease development, their suppressive activity needs to be measured.
Here, we describe a protocol to analyze the ex vivo phenotype of Treg cells and measure their suppressive activity using an in vitro co-culture system of CD8+ T cells and Treg cells. Critical steps in the current protocol are analysis and isolation of Treg cells. Live and freshly isolated Treg cells show clear suppressive activity in vitro. We also examined the phenotypes of Tconv and Treg cells during a chronic virus infection. Tconv cells, i.e., Foxp3–CD4+ and CD8+ T cells showed a decrease in cellular activity after the chronic virus infection (Figure 1). The PD-1 expression was upregulated in both the Tconv cell populations. Increase in Treg cell number and up-regulation of PD-1 expression are the hallmarks of immune response during a chronic virus infection. Additionally, anti-bodies for other inhibitory receptors such as TIM-3 and CTLA-4 can be used in combination with PD-1 to examine the T cell phenotype by FACS after choric virus infection.
In order to investigate the suppressive activity, Tresp cells and Treg cells were co-cultured at a ratio of 1 to 1. Co-culture with Treg cells from chronically infected mice significantly reduced CD8+ T cell proliferation and IFN-γ secretion when compared to Treg cells from naïve mice. This implies that the proliferation and cytokine production of CD8+ T cells co-cultured with Treg cells are inversely related to the suppressive function of Treg cells. Although this protocol recommends the use of a magnetic cell separation system for Treg cell isolation, contamination with non-Treg cells cannot be ruled out. The Treg cells obtained from Foxp3-GFP reporter mice28-30 are better candidates to accurately investigate the function of Treg cells than magnetic cell separation system, as CD25 is often overexpressed on activated CD4+ Tconv as well as Treg cells.
The suppressive function of Treg cells has been evaluated by various in vitro suppression assays16,28,31-34. The advantage of the in vitro suppression assay is that it evaluates the direct effect of Treg cells on the inhibition of the CD8+ T cell response, because only Tresp cells are co-cultured with Treg cells. In addition to CD8+ T cells, the CD25–CD4+ T cells can be used instead of Tresp cells25. The effects of Treg or Tconv cells on immune cells such as dendritic cells or natural killer cells can be evaluated by varying the experimental conditions.
Molecules such as the CD10335, LAG-336, glycoprotein A repetitions predominant37, CD4338, CD11a38, or killer cell lectin-like receptor subfamily G member 138 have been used as markers of activated Treg cells in specific diseases. In this protocol, we used PD-1 as an indicator to identify activated Treg cells during chronic virus infection. This protocol can be used for multifaceted analyses (phenotypic and functional) of Treg cells under specific conditions.
The authors have nothing to disclose.
This work was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2015R1A6A3A01020610 to HJP) and a grant from the Korean Health Technology R&D Project, Ministry for Health, Welfare and Family Affairs, Republic of Korea (HI15C0493 to SJH).
FITC Rat Anti-Mouse CD4 | RM4-5 | BD Biosciences | 553047 | Please determine appropriate concentration. In this protocol, this reagent was diluted 100X in FACS buffer. |
Cytofix/Cytoperm | BD Biosciences | 554714 | Use this reagent for cell surface staining. | |
U-Bottom Tissue Culture Plates | BD Biosciences | 353077 | ||
Fixation buffer | BD Biosciences | 554655 | Use this reagent for cell surface staining. | |
FITC Rat Anti-Mouse CD25 | 7D4 | BD Biosciences | 553072 | Please determine appropriate concentration. In this protocol, this reagent was diluted 100X in FACS buffer. |
Cell strainer, 70mm | BD Biosciences | 352350 | Use this strainer for grinding the whole spleen. | |
Cell strainer, 40mm | BD Biosciences | 352340 | Use this strainer for filtering the cells before column enrichment. | |
Brilliant Violet 421 Anti-mouse CD279 (PD-1) | 29F.1A12 | BioLegend | 135217 | Please determine appropriate concentration. In this protocol, this reagent was diluted 100X in FACS buffer. |
Brilliant Violet 605 Anti-Mouse CD4 | RM4-5 | Biolegend | 100547 | Please determine appropriate concentration. In this protocol, this reagent was diluted 100X in FACS buffer. |
APC Anti-Mouse/Rat Foxp3 | FJK-16s | eBioscience | 17-5773 | Please determine appropriate concentration. In this protocol, this reagent was diluted 100X in FACS buffer. |
Foxp3 / Transcription Factor Staining Buffer Set | eBioscience | 00-5223 | ||
PerCP-Cyanine5.5 Anti-Mouse CD8a | 53-6.7 | eBiosicence | 45-0081 | Please determine appropriate concentration. In this protocol, this reagent was diluted 100X in FACS buffer. |
Mouse IFN-gamma Platinum ELISA | eBiosicence | BMS606 | ||
RPMI 1640 | GE Life Sciences | SH30027 | ||
PBS (1X) | GE Life Sciences | SH30256 | ||
ACK Lysing Buffer | Gibco | A10492-01 | ||
L-Glutamine, 200mM solution | Gibco | 25030 | ||
Penicillin-Streptomycin, 10,000U/mL | Gibco | 10378-016 | ||
LIVE/DEAD Fixable Near-IR Dead Cell Stain Kit | Life technologies | L-34975 | Please determine appropriate concentration. In this protocol, this reagent was diluted 500X in FACS buffer. | |
CD8a+ T Cell Isolation Kit, mouse | Miltenyibiotec | 130-104-075 | ||
CD4+CD25+ Regulatory T Cell Isolation Kit, mouse | Miltenyibiotec | 130-091-041 | ||
MACS Separation Columns, LD columns | Miltenyibiotec | 130-042-901 | Use this column for Treg cell isolation | |
MACS Separation Columns, LS columns | Miltenyibiotec | 130-042-401 | Use this column for CD8+ T cell and Treg cell isolation | |
EDTA, 0.5M (pH 8.0) | Promega | V4231 | ||
2-Mercaptoethanol | Sigma Life Science | M7522 | ||
Fetal Bovine Serum | Thermo Fisher Scientific | SH30919.03 | ||
CellTrace Violet Cell Proliferation Kit | Thermo Fisher Scientific | C34557 | ||
BD Canto II flowcytometer | BD Biosciences | Flow cytometer* | ||
Flowjo | TreeStar | Flow cytometry software† | ||
Hematocytomer | Marienfeld superior |